Draft · 5 min read

Why ninety days

The clinical reasoning behind a 60-day supply and a 90-day trial.

The bottle is a 60-day supply. The trial window we suggest is 90 days. Neither number is a marketing choice — both come from the design of the studies the formula is built on.

Look at the trials behind the key ingredients. The ashwagandha study that established the 600 mg standardised-root dose ran for 60 days, with cortisol and stress-scale measures taken across the full course (Chandrasekhar et al., 2012). The dose-response study comparing 250 mg and 600 mg ran eight weeks (Salve et al., 2019). The rhodiola trial on stress-related fatigue measured fatigue scores, attention performance and morning cortisol response at 28 days, with effects building across that period (Olsson et al., 2009).

The pattern across the botanical literature is consistent: these are not acute interventions. Adaptogens modulate stress physiology gradually. A single dose does not do anything meaningful; a consistent daily dose over weeks does. Expecting a result in the first fortnight misreads how the ingredients work, and stopping at three weeks abandons the trial before the data arrives.

Ninety days gives the assessment a fair shape. It covers the full onset window the trials support — effects beginning around the one-month mark and consolidating through the second and third months — and it absorbs ordinary variation: a bad week of sleep, a stressful deadline, a travel disruption. Judging any intervention on its worst week produces the wrong answer.

There is a practical discipline that makes the window useful: decide what you're tracking before you start. Word retrieval. Afternoon mental fatigue. How often you lose the thread of something. Vague impressions drift; specific observations don't. If the fog is lighter at day ninety, you'll know it because you wrote down what it looked like at day one.

And if nothing has shifted by ninety days of consistent use, that is a legitimate result too. It means this isn't your answer — which is exactly what a trial is for, and why we'd rather you have a clear verdict than an open-ended subscription.

Brain fog, answered clinically.

Does perimenopause cause brain fog?

Yes — cognitive change is one of the most commonly reported experiences of the perimenopausal transition, and it is not imagined. Women describe it as word-finding difficulty, losing the thread mid-sentence, and recall that has become effortful rather than automatic.

The mechanism is hormonal rather than degenerative. Estrogen fluctuates erratically before it declines, and estrogen receptors are densely distributed in the hippocampus and prefrontal cortex — the regions that handle verbal memory and executive function. Sleep disruption and cortisol dysregulation during the same window compound the effect. Longitudinal research on midlife women has repeatedly found measurable changes in verbal memory across the transition, with most women returning to their own baseline afterwards.

What helps brain fog during perimenopause?

In clinical practice the levers are sleep quality, stress-axis regulation, and consistent support of the systems affected by fluctuating hormones — not stimulants, which tend to borrow clarity from the following day.

Cycle + Thrive was formulated around that reasoning: adaptogenic and botanical ingredients at full clinical doses, chosen for their role in cortisol regulation, sleep architecture and cognitive resilience rather than for label appeal. Read the ingredient-by-ingredient rationale on The Formula, and the reasoning behind the 90-day assessment window on The Science.

This is educational information, not medical advice. Cognitive change has other possible causes — thyroid dysfunction, anemia, sleep apnea, medication effects — and is worth investigating with your clinician.

Why ninety days

Brain fog, answered clinically.

The perimenopause research, simplified.